B-cell-targeted therapy for systemic lupus erythematosus-associated warm autoimmune haemolytic anaemia: a real-world comparative cohort study

Clicks: 18
ID: 329942
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #211 of 339 articles by views in Lara D. Veeken

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 339 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
OBJECTIVES: To compare B-cell-targeted therapy with conventional glucocorticoid-based immunosuppression in first-episode systemic lupus erythematosus (SLE)-associated warm autoimmune haemolytic anaemia (AIHA). METHODS: We conducted a multicampus retrospective cohort study from 1 March 2020 to 1 February 2026. Eligible patients had SLE-associated warm AIHA, baseline haemoglobin <90 g/L and laboratory evidence of haemolysis. Treatment exposure was classified within 14 days of treatment initiation: conventional therapy or B-cell-targeted therapy with rituximab, belimumab or telitacicept. The primary outcome was 6-month overall response rate (ORR; complete or partial response). RESULTS: Of 246 SLE hospitalisation records screened, 70 patients were included; 27 received conventional therapy and 43 received B-cell-targeted therapy. The B-cell-targeted therapy group was younger and had higher baseline SLEDAI-2K scores. Six-month ORR was 89.7% with B-cell-targeted therapy and 85.7% with conventional therapy (OR 1.45, 95% CI 0.19-9.61; P = 0.687), with corresponding complete response rates of 61.5% and 42.9%. At 1 month, prednisone-equivalent dose was lower with B-cell-targeted therapy (40.0 vs 50.0 mg/day; P = 0.023). Twelve-month ORR was 89.3% with B-cell-targeted therapy and 73.7% with conventional therapy, and relapse-free survival did not differ significantly. Within 6 months, 13 inpatient-recorded adverse-event episodes, including fatal events, were documented. In telitacicept-treated patients (n = 7), all evaluable patients achieved ORR at 1, 3 and 6 months. CONCLUSIONS: Six- and 12-month ORR did not differ significantly between treatment strategies. The numerically higher complete response rate, more stable 12-month response and earlier glucocorticoid reduction with B-cell-targeted therapy, together with the telitacicept findings, are exploratory and require prospective validation.
Reference Key
openalex_W7214324998 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Yiduo Sun, Yuting Wang, Heng Cao, Yini Ke, Weiqian Chen, Chris Wincup, Jin Lin
Are you one of these authors? Claim your profile
Journal Lara D. Veeken
Year 2026
DOI
10.1093/rheumatology/keag535
URL
https://doi.org/10.1093/rheumatology/keag535
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.